Relmada Therapeutics Inc (RLMD)

Currency in USD
0.568
-0.020(-3.40%)
Closed·
0.590+0.022(+3.82%)
·
RLMD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
RLMD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.5560.590
52 wk Range
0.2403.980
Key Statistics
Prev. Close
0.568
Open
0.59
Day's Range
0.556-0.59
52 wk Range
0.24-3.98
Volume
208.59K
Average Volume (3m)
430.57K
1-Year Change
-77.64%
Book Value / Share
0.48
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RLMD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.000
Upside
+76.06%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Relmada Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Relmada Therapeutics Inc Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Relmada Therapeutics Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of -$0.58 missed forecast of -$0.37; stock fell 2.08% in aftermarket trading
  • Cash balance decreased to $27.1M from $44.9M; R&D expenses down to $12M, G&A expenses reduced to $6.3M
  • NDV-one for bladder cancer showed 85% response rate; FDA interactions and manufacturing expansion planned
  • CEO highlights strong start to 2025 with two new product candidates; aims for US IND clearance in H2 2025
  • Analysts focused on FDA interaction plans and competitive positioning of NDV-one in earnings call Q&A
Last Updated: 12/05/2025, 22:18
Read Full Transcript

Compare RLMD to Peers and Sector

Metrics to compare
RLMD
Peers
Sector
Relationship
P/E Ratio
−0.3x−4.4x−0.5x
PEG Ratio
−0.010.000.00
Price/Book
1.2x2.7x2.6x
Price / LTM Sales
-1.7x3.3x
Upside (Analyst Target)
70.1%69.4%40.3%
Fair Value Upside
Unlock10.1%4.7%Unlock

Analyst Ratings

0 Buy
2 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 1.000
(+76.06% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.30 / -0.40
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

RLMD Income Statement

People Also Watch

2.020
VOR
+21.69%
20.40
SRPT
+8.51%
2.56
INMB
+5.79%
0.536
WINT
+3.47%
0.400
ADIL
+1.27%

FAQ

What Stock Exchange Does Relmada Therapeutics Trade On?

Relmada Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Relmada Therapeutics?

The stock symbol for Relmada Therapeutics is "RLMD."

What Is the Relmada Therapeutics Market Cap?

As of today, Relmada Therapeutics market cap is 18.86M.

What Is Relmada Therapeutics's Earnings Per Share (TTM)?

The Relmada Therapeutics EPS (TTM) is -2.19.

When Is the Next Relmada Therapeutics Earnings Date?

Relmada Therapeutics will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is RLMD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Relmada Therapeutics Stock Split?

Relmada Therapeutics has split 2 times.

How Many Employees Does Relmada Therapeutics Have?

Relmada Therapeutics has 17 employees.

What is the current trading status of Relmada Therapeutics (RLMD)?

As of 14 Aug 2025, Relmada Therapeutics (RLMD) is trading at a price of 0.57, with a previous close of 0.57. The stock has fluctuated within a day range of 0.56 to 0.59, while its 52-week range spans from 0.24 to 3.98.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.